TRACON Pharmaceuticals, Inc. Common Stock
TCON
TCON was delisted on the 27th of June, 2024.
25 hedge funds and large institutions have $16.4M invested in TRACON Pharmaceuticals, Inc. Common Stock in 2016 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
14% more funds holding
Funds holding: 22 → 25 (+3)
46% less capital invested
Capital invested by funds: $30.4M → $16.4M (-$14M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$246K |
| 2 |
Stifel Financial
St. Louis,
Missouri
|
+$219K |
| 3 |
CAM
ClariVest Asset Management
San Diego,
California
|
+$136K |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$66.3K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$21.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$2.18M |
| 2 |
VAM
Visium Asset Management
New York
|
-$2.04M |
| 3 |
WG
Welch Group
Birmingham,
Alabama
|
-$418K |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$133K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$106K |
TCON Hedge Fund Activity: Q2 2016 in Review
25 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in TRACON Pharmaceuticals, Inc. Common Stock (TCON) for Q2 2016, worth a combined $16.4M — down 46% from $30.4M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new TCON positions and 1 closed out — a net gain of 3 holders — while 6 added to existing stakes and 5 trimmed.
The largest buyer was Jacobs Levy Equity Management, opening a new position worth an estimated $246K. The largest seller was Deerfield Management, cutting an estimated $2.18M.
- 25 institutional investors held TRACON Pharmaceuticals, Inc. Common Stock (TCON) as of Q2 2016, up from 22 in Q1 2016.
- Funds reported $16.4M of TRACON Pharmaceuticals, Inc. Common Stock stock for Q2 2016, down 46% quarter-over-quarter.
- 4 funds opened new TRACON Pharmaceuticals, Inc. Common Stock positions in Q2 2016 and 1 closed out, a net change of +3 holders.
- The largest TRACON Pharmaceuticals, Inc. Common Stock buyer in Q2 2016 was Jacobs Levy Equity Management, an estimated $246K added.
- The largest TRACON Pharmaceuticals, Inc. Common Stock seller in Q2 2016 was Deerfield Management, an estimated $2.18M sold.
Based on aggregated 13F filings for Q2 2016.